Bristol Myers Squibb Slashes Price of Psoriasis Drug Sotyktu by Over 80% for Eligible Patients

Gelonghui September 25 | Bristol-Myers Squibb announced that it will offer its drug Sotyktu for moderate to severe plaque psoriasis at a discounted price, which is 80% lower than the current listed price, to eligible patients. Previously, the company also announced a discount plan for the anticoagulant drug Eliquis in response to the Trump administration’s call for the pharmaceutical industry to lower drug prices.